Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01577355 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2784544 in Healthy Male Subjects
A Phase 1 study of Healthy Male Volunteers, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01577355 is a Phase 1 study of Healthy Male Volunteers that has completed, run by Eli Lilly and Company. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01577355, a Phase 1 study of Healthy Male Volunteers, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single dose study of radiolabelled LY2784544 in healthy male subjects to study the absorption, distribution, metabolism and excretion of LY2784544. This study is for research purposes only and is not intended to treat any medical condition.
Conditions Studied
Interventions
- RADIATION Drug
Study Locations (1)
Wisconsin
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01577355
The ClinicalTrials.gov registry entry for NCT01577355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Male Volunteers appearing as the primary indexed condition, and to 1 intervention - of which Drug is the first listed.
NCT01577355 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01577355 about?
NCT01577355 is a clinical study titled "A Study of LY2784544 in Healthy Male Subjects". This is a single dose study of radiolabelled LY2784544 in healthy male subjects to study the absorption, distribution, metabolism and excretion of LY2784544. This study is for research purposes only and is not intended to treat any medical condition.
What is the current status of trial NCT01577355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2012-04. Estimated completion is 2012-06.
What conditions does trial NCT01577355 study?
This clinical trial studies the following conditions: Healthy Male Volunteers.
What interventions are being tested in trial NCT01577355?
The interventions under investigation include: Drug (RADIATION).
Who is sponsoring clinical trial NCT01577355?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01577355 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Male Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.